Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVac in resected stage I/II pancreatic cancer
NCT02310971Phase 2Withdrawn
- Sponsor
- Immutep Limited
- Start
- Feb 2015
- Primary completion
- Mar 2015
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of CVac in pancreatic adenocarcinoma (PDAC), sponsored by Immutep Limited. Planned start Feb 2015; status: withdrawn.
02
Drugs
CVac
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02310971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310971.